Federation Des Caisses Desjardins Du Quebec Tg Therapeutics, Inc. Transaction History

Federation Des Caisses Desjardins Du Quebec

$18.9 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$13.02 - $21.3 $520 - $852	40 New	40 $608,000
Q1 2018 Aug 30, 2024	SELL	$8.7 - $16.8 $14,789 - $28,560	-1,700 Closed	0 $0
Q4 2017 Aug 30, 2024	BUY	$7.35 - $12.3 $12,495 - $20,910	1,700	1,700 $13.9 Million

Others Institutions Holding TGTX

# of Institutions

337

Shares Held

87.7M

Call Options Held

2.35M

Put Options Held

1.7M

Vanguard Group Inc Valley Forge, PA

15.4M
Shares

$431 Million
0.01% of portfolio
Black Rock Inc. New York, NY

11.4M
Shares

$319 Million
0.0% of portfolio
State Street Corp Boston, MA

9.09M
Shares

$255 Million
0.01% of portfolio
Pictet Asset Management Holding Sa Carouge, V8

3.58M
Shares

$100 Million
0.1% of portfolio
Geode Capital Management, LLC Boston, MA

3.21M
Shares

$89.7 Million
0.01% of portfolio

View Full List

About TG THERAPEUTICS, INC.

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.07B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

More about TGTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account